<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2201">
  <stage>Registered</stage>
  <submitdate>3/12/2008</submitdate>
  <approvaldate>3/12/2008</approvaldate>
  <nctid>NCT00801957</nctid>
  <trial_identification>
    <studytitle>Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis</studytitle>
    <scientifictitle>A Double Blind, Multicentre, Randomised, Parallel Group Study to Demonstrate the Equivalence of the Response to Vaccination of a Tacrolimus Ointment Regimen to a Steroid Ointment Regimen in Children With Moderate to Severe Atopic Dermatitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FG-506-06-27</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atopic Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - tacrolimus ointment 0.03%
Treatment: drugs - hydrocortisone acetate ointment 1%
Treatment: drugs - hydrocortisone butyrate ointment 0.1%
Other interventions - Meningitec
Other interventions - AC VAX

Experimental: 1 - tacrolimus ointment 0.03%

Active Comparator: 2 - hydrocortisone acetate 1% and butyrate 0.1%

Other: 3 - Control group vaccination and challenge dose only


Treatment: drugs: tacrolimus ointment 0.03%
topical application

Treatment: drugs: hydrocortisone acetate ointment 1%
topical application

Treatment: drugs: hydrocortisone butyrate ointment 0.1%
topical application

Other interventions: Meningitec
im injection

Other interventions: AC VAX
im injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of patients with serum bactericidal antibody titer of = 8</outcome>
      <timepoint>5 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of other immunological parameters</outcome>
      <timepoint>7 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients with moderate to severe atopic dermatitis and in need for treatment

          -  Patients require vaccination to prevent invasive disease caused by Neisseria
             meningitidis serogroup C</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>11</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients have known hypersensitivity to macrolides, tacrolimus and any component of
             the vaccine

          -  Patients have an acute severe febrile illness, genetic epidermal barrier defect such
             as Netherton's syndrome or generalized erythroderma, a skin infection on the affected
             and to be treated area

          -  Patients have already received a meningo polysaccharide or conjugated vaccine against
             meningitis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>260</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital> - Kogarah</hospital>
    <hospital> - St. Leonards</hospital>
    <hospital> - Benowa</hospital>
    <hospital> - Carina Heights</hospital>
    <hospital> - Herston</hospital>
    <hospital> - North Adelaide</hospital>
    <hospital> - Carlton</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Fremantle</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode>4152 - Carina Heights</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bretten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ettenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gersfeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kehl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tettnang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Iceland</country>
      <state>Kopavogur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malta</country>
      <state>St. Julians</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Karpacz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Opole</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Rabka-Zdroj</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Zabrze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Zgierz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas Pharma Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Seven-month study in pediatric patients (2-11 years) with moderate to severe AD who were
      considered to benefit from vaccination to prevent invasive disease caused by Neisseria
      meningitides serogroup C.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00801957</trialwebsite>
    <publication>Hofman T, Cranswick N, Kuna P, Boznanski A, Latos T, Gold M, Murrell DF, Gebauer K, Behre U, Machura E, Olafsson J, Szalai Z; International Tacrolimus Ointment Study Group. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child. 2006 Nov;91(11):905-10. Epub 2006 Jun 23. Erratum in: Arch Dis Child. 2007 Jan;92(1):93.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Central Contact</name>
      <address>Astellas Pharma Europe B.V.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>